Subscribe

Dotz Nano Limited (DTZ.AX)

AUD0.03 +0.00 (+8.70%)
IL ASX Basic Materials Chemicals - Specialty
Address 1 Atir Yeda 4464301
Kfar Saba, IL
CEO Sharon Malka
Website dotz.tech
IPO 2007-12-12
ISIN AU000000DTZ4

Explore sections of this company profile

Description

Dotz Nano Limited is dedicated to creating and commercializing advanced carbon-based materials that provide crucial solutions for tracing products, preventing counterfeiting, and addressing product liability. The company offers a suite of proprietary technologies, including ValiDotz, BioDotz, Fluorensic, and InSpec, which find application across numerous sectors. These range from enhancing brand security and safeguarding reputation to specialized uses in the oil and gas industry, tagging liquids, lubricants, and polymers, as well as in bio-imaging. Dotz Nano distributes its offerings globally, utilizing a network of partners in regions such as North America, Europe, Japan, China, and Australia. The company also fosters scientific alliances with various academic institutions and has a significant collaboration with Theracell Labs Ltd for the co-development, supply, and licensing of disposable bioprocessing consumables. Dotz Nano Limited's headquarters are located in Kfar Saba, Israel.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
AUD0.03 +0.00 (+8.70%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
517.5K
Beta
0.30
Float Shares
601.89M
Free Float %
86.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-6.67% +7.69% +31.25% +13.51% -25.00% +5.00% -12.50% -84.15% -88.00% -99.53% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.03
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-54.90
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Chemicals - Specialty: +4.7%
    — Q4'25: +12.9% (vs Q4'23)
  • ✗
    EPS growth Chemicals - Specialty: +13.2%
    -45.4% Q4'25: -76.9% (vs Q4'23)
  • ✗
    FCF margin FCF growth · Chemicals - Specialty: +44.1%
    -961.2% Q4'25: -1,307.6% (vs Q4'23)
  • ✗
    EBIT margin Chemicals - Specialty: +8.8%
    -1,241.6% Q4'25: -3,145.4% (vs Q4'23)
  • ✓
    ROIC Chemicals - Specialty: +5.6%
    — Q4'25: +2,539.6% (vs Q4'23)
  • ✗
    Share dilution Chemicals - Specialty: +0.1%
    +12.5% Q4'25: +22.4% (vs Q4'23)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×
    -1.43× Q4'25: -0.56× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.25) × ERP
WACC = 81% × Ke + 19% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.03
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana.
Revenue
42.01M
est: 190.32M (-77.9%)
—
est: 206.85M (-100.0%)
108.3K
est: 275.74M (-100.0%)
15.4K
est: 201.94M (-100.0%)
33.7K
est: 202.03M (-100.0%)
375.8K
est: 274.54M (-99.9%)
304.6K
est: 25.30M (-98.8%)
191.9K
est: 47.77M (-99.6%)
53.0K
est: 95.25M (-99.9%)
—
est: 86.60M (-100.0%)
295.7K
est: 238.89M (-99.9%)
238.89M
238.89M – 238.89M
+0.0% YoY
23.29M
23.29M – 23.29M
-90.3% YoY
46.65M
46.65M – 46.65M
+100.3% YoY
93.36M
93.36M – 93.36M
+100.1% YoY
EBITDA
-123.30M
est: -114.19M (-8.0%)
-7.69M
est: -124.11M (+93.8%)
-4.50M
est: -165.44M (+97.3%)
-5.62M
est: -121.17M (+95.4%)
-3.51M
est: -121.22M (+97.1%)
-3.95M
est: -164.72M (+97.6%)
-7.75M
est: -15.18M (+48.9%)
-4.79M
est: -28.66M (+83.3%)
-5.13M
est: -57.15M (+91.0%)
-4.66M
est: -51.96M (+91.0%)
-2.96M
est: -143.33M (+97.9%)
-143.33M
-143.33M – -143.33M
+0.0% YoY
-13.97M
-13.97M – -13.97M
+90.3% YoY
-27.99M
-27.99M – -27.99M
-100.3% YoY
-56.02M
-56.02M – -56.02M
-100.1% YoY
EBIT
-131.89M
est: -114.19M (-15.5%)
-5.59M
est: -124.11M (+95.5%)
-4.55M
est: -165.44M (+97.2%)
-5.70M
est: -121.17M (+95.3%)
-3.73M
est: -121.22M (+96.9%)
-4.04M
est: -164.72M (+97.6%)
-7.83M
est: -15.18M (+48.4%)
-4.88M
est: -28.66M (+83.0%)
-5.48M
est: -57.15M (+90.4%)
-4.74M
est: -51.96M (+90.9%)
-3.67M
est: -143.33M (+97.4%)
-143.33M
-143.33M – -143.33M
+0.0% YoY
-13.97M
-13.97M – -13.97M
+90.3% YoY
-27.99M
-27.99M – -27.99M
-100.3% YoY
-56.02M
-56.02M – -56.02M
-100.1% YoY
Net Income
-134.27M
est: -27.13B (+99.5%)
-8.09M
est: -8.51B (+99.9%)
-4.73M
est: 26.17B (-100.0%)
-5.74M
est: -28.79B (+100.0%)
-3.75M
est: -8.31B (+100.0%)
-3.97M
est: 26.06B (-100.0%)
-7.94M
est: -38.80M (+79.5%)
-5.37M
est: -562.9K (-854.6%)
-6.57M
est: 57.07M (-111.5%)
-5.76M
est: 58.39M (-109.9%)
-9.43M
est: 25.51B (-100.0%)
25.51B
25.51B – 25.51B
+0.0% YoY
-40.20M
-40.20M – -40.20M
-100.2% YoY
-618.5K
-618.5K – -618.5K
+98.5% YoY
62.95M
62.95M – 62.95M
+10,277.4% YoY
SGA
457.3K
est: 4.35B (-100.0%)
4.94M
est: 4.73B (-99.9%)
2.24M
est: 6.31B (-100.0%)
4.34M
est: 4.62B (-99.9%)
2.59M
est: 4.62B (-99.9%)
3.35M
est: 6.28B (-99.9%)
5.96M
est: 578.49M (-99.0%)
3.06M
est: 1.09B (-99.7%)
3.66M
est: 2.18B (-99.8%)
3.42M
est: 1.93B (-99.8%)
1.87M
est: 5.34B (-100.0%)
5.34B
5.34B – 5.34B
+0.0% YoY
520.43M
520.43M – 520.43M
-90.3% YoY
1.04B
1.04B – 1.04B
+100.3% YoY
2.09B
2.09B – 2.09B
+100.1% YoY
EPS
-277.19
est: -51.05 (-443.0%)
-0.33
est: -16.01 (+97.9%)
-0.04
est: 49.24 (-100.1%)
-0.04
est: -54.17 (+99.9%)
-0.02
est: -15.63 (+99.9%)
-0.01
est: 49.02 (-100.0%)
-0.02
est: -0.07 (+72.9%)
-0.01
est: 0.00 (-1,042.5%)
-0.01
est: 0.11 (-112.8%)
-0.01
est: 0.10 (-111.1%)
-0.02
est: 42.66 (-100.0%)
42.66
42.66 – 42.66
+0.0% YoY
-0.07
-0.07 – -0.07
-100.2% YoY
0.00
0.00 – 0.00
+98.5% YoY
0.11
0.11 – 0.11
+10,277.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-26 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-25 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-19 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-14 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-13 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-11 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-08 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-01 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-17 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-16 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-5.50M
OE per share TTM
-0.01
Owner's Yield
-21.54%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
331.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-105.00
Shares Outstanding
693.10M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Sharon Malka MD, Chief Executive Officer & Executive Director 560.6K male
Liat Bar Ziv Alperovitz Chief Financial Officer 299.6K female
Bernard Joseph Brookes Ed Independent Non-Executive Chairman & Company secretary 107.9K male
Daniel Vorenberg Head of Engineering — male
James Tour Co-Founder & Scientific Advisor — —
Shirley Shoshaney-Kleiner C.M.O. — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Chemicals - Specialty